Articles tagged with Melanoma
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Organ transplant recipients are more susceptible to developing regional stage melanoma due to immunosuppressive medications. The study found that transplant patients were four times more likely to be diagnosed with regional stage melanoma and three times more likely to die from the disease.
Researchers at UC Davis found that a novel combination therapy of Interleukin (IL)-2 combined with imiquimod and topical retinoid is highly effective in treating patients with skin metastases, resulting in complete clinical response and high survival rates.
The University of Kentucky's Dr. John D'Orazio is leading a 3-year research project on melanoma, the deadliest form of skin cancer, with a focus on hormonal pathways and DNA repair. The study aims to understand how specific hormones affect melanocortin1 receptor signaling, which is linked to an increased risk of developing melanoma.
Scientists have uncovered five new common genetic risk factors for melanoma and confirmed two others, establishing the role of telomeres in its development. Skin pigmentation is also a key genetic determinant, emphasizing the importance of sun protection for individuals with pale skin and many moles.
A Yale study identified NF1 as a key gene in melanoma development and progression. The research revealed that 45% of melanomas without known BRAF or NRAS mutations display loss of NF1 function, leading to cancer-causing pathways.
Researchers Neil Ganem and Anurag Singh at Boston University School of Medicine are developing new strategies to inhibit the growth of chromosomally unstable cancer cells expressing oncogenic BRAF. They have identified two major types of NRAS networks in melanoma, which may be targeted with selective anti-cancer agents.
A large analysis suggests frequent citrus fruit and juice consumption may increase melanoma risk by 36% in people who eat them daily. The association is strongest for grapefruit, but not processed juices.
Researchers from Umea University found no association between PDEi drugs and increased melanoma risk; instead, men taking these drugs are more health-conscious and sunbathe more often, increasing their melanoma diagnosis risk.
A study found that use of phosphodiesterase type 5 inhibitors for erectile dysfunction was associated with a modest but significant increased risk of malignant melanoma in Swedish men. The most pronounced increase in risk was observed in men who had filled a single prescription, but not among those with multiple prescriptions.
Google searches for information on melanoma and skin cancer rose over summer months from 2010 to 2014. The correlation between these searches and actual melanoma incidence and mortality rates was limited, suggesting that increased search volumes do not necessarily translate to improved detection rates.
Clinical trials demonstrate improved survival rates for patients with metastatic melanoma using immune therapies nivolumab and pembrolizumab. These treatments target the 'don't attack' protein PDL1 on tumors, allowing the immune system to prime against tumor tissue.
Researchers found that combining immunotherapy drugs nivolumab and ipilimumab significantly increases progression-free survival in advanced melanoma patients, with a median PFS of 11.5 months compared to 6.9 months for nivolumab alone.
Nivolumab has shown promise as a therapeutic agent for improving survival rates in melanoma patients. The most common adverse events were fatigue, pruritus, diarrhea, and rash, which were primarily low-grade and manageable with immunomodulatory agents.
Researchers found traditional teaching methods focus on factual knowledge rather than visual training, leading to improved results with perceptual training modules. Undergraduate students reached expertise in identifying skin cancers and benign lesions within two hours of training.
Researchers from NYU Langone present 30 abstracts on various cancer types, including immunotherapy studies for melanoma and pediatric leukemia. Key findings highlight the potential for personalized medicine and improved outcomes in cancer patients.
A phase 3 international trial found that ipilimumab improved recurrence-free survival in advanced stage melanoma patients who underwent surgical resection. The study showed that patients with microscopic metastatic disease responded best to ipilimumab treatment.
Researchers found hundreds of possible new genes that could transform benign skin growths into deadly melanomas when combined with the Braf V600E mutation. The discovery provides new targets for slowing or stopping cancer growth.
A recent EORTC trial found that adjuvant Ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence. However, the treatment was also associated with a high rate of immune-related adverse events.
A multicenter clinical trial launched by Yale University aims to evaluate the effectiveness of personalized medicine in treating metastatic melanoma. The trial will enroll patients lacking a particular genetic mutation and use molecular sequencing techniques to match targeted drugs to unique genetic alterations.
Researchers have linked a new protein, megalin, to aggressive malignant melanoma cells that are more likely to spread. The protein's presence can improve cancer cell division and survival, making it a potential marker for early detection and targeted treatment options.
Researchers found a decrease in pediatric melanoma cases in the US from 2000-2010, with an overall decline of 12% per year. The number of new cases decreased in boys and adolescents, particularly those with good prognostic indicators.
A Yale study found that one in five Medicare patients with melanoma experience significant delays in getting surgery, affecting their psychological well-being and healthcare quality. The study analyzed data from over 32,000 Medicare patients and revealed that 22% waited longer than 1.5 months for treatment.
A study of 32,501 melanoma cases found that 1 in 5 patients experienced a delay of surgery lasting longer than 1.5 months. Surgical delays were more common among older patients and those with prior melanoma or multiple medical conditions.
Researchers found that Nodal protein promotes melanoma cell growth and survival, leading to improved treatment outcomes with anti-Nodal antibody combinations. The study provides hope for patients with metastatic melanoma, a disease with limited treatment options.
A case-control study of over 180,000 men found that men with testicular cancer have a higher incidence of prostate cancer compared to those without a history of the disease. The study revealed a significant increase in aggressive prostate cancers among men with testicular cancer.
Researchers at MD Anderson Cancer Center have identified unique 'protein patterns' in melanoma patients to predict resistance to BRAF inhibitors. These patterns may help guide personalized treatment decisions, including targeted agents or immunotherapies.
Experts suggest that targeted screening programs for middle-aged and older patients using newer diagnostic tools could significantly reduce melanoma mortality rates. Studies in Australia and Germany have shown a substantial decrease in melanoma-related deaths after implementing comprehensive skin cancer screening programs.
Epidemiological and pre-clinical studies suggest coffee has a protective effect against non-melanoma skin cancers, but the link to cutaneous melanoma is less clear. A study found that high coffee intake was inversely associated with a 20% lower risk of malignant melanoma, especially in caffeinated coffee drinkers.
A University of Colorado Cancer Center study found that TAK-733, a next-gen melanoma drug, exhibited anti-cancer activity in 10 out of 11 patient tumor samples grown in mice. The drug showed significant shrinkage in tumors up to 100%, regardless of BRAF mutation status.
The Myriad myPath Melanoma test has been shown to improve patient care through more definitive diagnoses of skin lesions, particularly in difficult-to-call cases. This resulted in a 49% change in physicians' treatment recommendations for patients with melanoma subtypes.
A phase 2 clinical trial found that combining ipilimumab with sargramostim improved overall survival by nearly five months and reduced serious side effects. The treatment combination also showed a higher one-year survival rate of 68.9% compared to 52.9% in the ipilimumab-only group.
A phase 2 clinical trial found that adding sargramostim to ipilimumab improved overall survival in patients with metastatic melanoma. The combination treatment also had lower toxicity compared to ipilimumab alone.
Researchers found melanoma cells create their own 'green light' signal using lysophosphatidic acid (LPA) to spread quickly and aggressively. This 'breadcrumb trail' allows cancer cells to travel rapidly around the body, making treatment challenging.
Researchers analyzed cultural and historical forces to estimate historic changes in UV exposure contributing to the rise in melanoma cases. Changes in fashion and clothing design, as well as increased leisure time and sun exposure, are identified as key factors.
Preliminary data from a phase III trial suggest nivolumab achieves better response rates and longer response durations than standard chemotherapy in patients with unresectable metastatic melanoma. The drug has a lower toxicity profile compared to chemotherapy, promoting a sustained immune response.
Combination therapy with vemurafenib and cobimetinib achieves greater progression-free survival and response rates than vemurafenib alone in BRAF-mutation positive melanoma. The study also shows a reduced incidence of skin-related side-effects with combination therapy.
A phase 3 trial found that combining dabrafenib with trametinib significantly reduces disease progression and death risk in metastatic melanoma patients. The therapy results in a 67% complete or partial response rate compared to 51% on monotherapy.
The European Organisation for Research and Treatment of Cancer (EORTC) will showcase its latest cancer research findings at the ESMO 2014 Congress. The conference will feature various sessions, including a joint symposium on clinical trials and posters focused on immunotherapy and gastrointestinal tumors.
A recent study published in the Journal of the National Cancer Institute has established a link between longer telomeres and increased melanoma risk. The research team identified seven genetic variations associated with telomere length and found that those with the longest telomeres are at a 30% increased risk of developing melanoma.
A new study from the University of Leeds has uncovered a genetic risk factor for melanoma, with longer telomeres associated with a higher risk. The research found that individuals with shorter telomeres are at a 30% increased risk of developing melanoma.
The Wistar Institute and Penn Medicine have collaborated on a $12.1 million SPORE grant to develop new therapies for melanoma. The goal of this project is to translate fundamental laboratory discoveries into new therapeutics that will benefit patients with melanoma and other skin cancers.
A retrospective study found that 62% of veterans reported getting sunburned while deployed, and 29% noticed changes in their moles, highlighting a potential deficiency in sun protection among military personnel. The study suggests room for improvement in skin cancer prevention and early detection in the military population.
The myPath Melanoma test differentiates malignant melanoma from benign skin lesions with over 90% accuracy, reducing indeterminate diagnoses by 76%. This improved diagnostic tool also changed treatment recommendations in 35% of cases, supporting its integration into clinical practice.
A systematic review and meta-analysis of 19 studies found that airline pilots and cabin crews have a higher incidence of melanoma, with a combined standardized incidence ratio of 2.21 for any flight-based occupation. This increased risk is attributed to exposure to UV radiation during flights.
Acral melanomas, which affect the hands and feet, have unique DNA damage patterns not caused by UV radiation. Researchers sequenced tumor samples and found distinct genetic faults driving this rare skin cancer. Understanding these faults may lead to better treatments for acral melanoma.
A study found that high-mitotic rate melanomas are more likely to occur on the head and neck, grow rapidly, and be present in older men with a history of solar keratosis. These tumors have distinct clinical features, including nodular structure and amelanosis, which may pose a challenge to timely detection.
Researchers have developed a new hand-held device that uses photoacoustic microscopy to accurately measure the depth of melanoma tumors in living tissue. This technology has the potential to improve diagnosis, prognosis, and treatment planning for melanoma patients by providing valuable information on tumor volume.
A new UK study reveals that a genetic defect in the melanocortin1 receptor (MC1R) may make people more susceptible to developing melanoma. The study found that MC1R defects contribute to melanoma development by delaying DNA repair and increasing cancerous mutations.
Research conducted at Texas Biomedical Research Institute found that sunscreen use in infancy and childhood reduces malignant melanoma incidence in adulthood by 10-fold. The study used a natural animal model, gray short-tailed opossums, to test the effectiveness of sunscreen against UV-induced melanoma.
A study found that selumetinib improved cancer progression-free survival time and tumor response rate in patients with advanced uveal melanoma, but had no impact on overall survival. Treatment-related adverse events were common, affecting nearly all patients.
A comprehensive clinical trial found that SPECT/CT imaging detected significantly more sentinel lymph node involvement with various types of cancers, including melanoma, breast carcinoma, and pelvic malignancies. This improved imaging technique has the potential to alter surgical planning and improve patient outcomes.
Researchers have made significant strides in developing innovative immunotherapies that activate the body's immune response to fight cancer. The new treatments show high activity against advanced melanoma and demonstrate substantial decrease in melanoma recurrence risk.
The Myriad myPath Melanoma test accurately differentiates malignant melanoma from benign skin lesions with a sensitivity of 90% and specificity of 91%. This improves the standard of care for patients with melanoma, enabling healthcare providers to deliver more objective and confident diagnoses.
A study by Mayo Clinic researchers found that the size of tumors before treatment is a strong predictor of response to immunotherapy drug MK-3475. The findings suggest that decreasing baseline tumor size through surgery or other means may be more effective in inducing long-lasting remissions.
A rare type of melanoma that affects darker skins is almost twice as likely to recur as other similar types of skin cancer. The study found that acral lentiginous melanoma has a high recurrence rate, especially in small tumors.
A study published in JNCI: Journal of the National Cancer Institute found that indoor tanning increases melanoma risk, regardless of burn history. Researchers matched 1167 melanoma patients with 1101 control subjects and found nearly four times more indoor tanners among those with zero burns.
Researchers at Cancer Research UK Manchester Institute have found that blocking the MLK family of four enzymes can prevent rapid resistance to vemurafenib, a treatment for advanced melanoma. This breakthrough could lead to new targeted therapies for metastatic melanomas with limited treatment options.
A sunburn risk monitor, Smartsun, is now available for purchase online. The device, worn as a waterproof wristband, changes color in response to UV radiation levels, warning users of potential skin damage.
Researchers found that patients who visited a specialist prior to melanoma diagnosis had a significantly lower risk of dying from the disease. This suggests that being invested and an advocate for one's own health may play a crucial role in improving prognosis.
The technology is being showcased at the AACR Annual Meeting, where researchers are highlighting its potential for cancer research. Studies have demonstrated the use of ddPCR to track treatment response in melanoma patients and quantify mutant genes in plasma and serum.